acetylcysteine administration in treatment of metabolic syndrome

Phase 3

• Conditions: Metabolic syndrome.; Metabolic syndrome; E88.81

• Registration Number: IRCT20170513033941N72
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Patients diagnosed with metabolic syndrome
Individuals aged 25-75 years old

Exclusion Criteria

Patients with infectious, malignant and inflammatory diseases
Those taking any antioxidant and/or anti-inflammatory supplements within 16 weeks prior to enrollment in the study
Hypersensitivity to the study medication
Pregnancy or breastfeeding
Diabetes mellitus

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using the Homeostasis Model Assessment (HOMA) formula.